We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SELENOF is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
204.0
Number of samples
141
Samples
Sample
Description
TPM
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
605.0
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
548.0
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
431.2
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
406.4
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
387.1
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
371.1
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
348.6
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
342.2
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
334.7
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
331.5
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
327.0
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
311.0
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
303.0
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
301.3
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
300.2
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
296.4
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
293.9
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
291.0
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
288.5
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
284.9
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
275.6
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
273.6
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
268.6
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
268.6
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
264.7
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
262.6
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
260.3
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
259.3
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
257.4
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
252.6
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
245.5
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
244.2
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
242.6
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
239.8
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
237.5
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
234.2
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
233.4
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
232.8
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
232.3
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
228.0
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
226.8
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
226.5
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
225.2
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
225.0
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
222.5
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
222.2
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
222.2
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
222.0
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
219.6
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
217.8
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
216.9
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
215.7
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
214.6
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
214.6
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
214.3
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
214.2
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
210.3
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
208.7
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
207.4
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
205.6
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
205.6
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
203.6
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
202.4
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
201.9
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
201.1
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
201.0
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
200.6
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
199.2
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
196.2
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
194.6
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
193.6
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
190.3
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
188.0
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
187.9
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
184.7
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
183.2
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
182.6
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
182.4
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
180.7
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
179.0
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
177.5
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
176.5
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
176.4
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
173.2
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
172.4
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
169.5
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
169.3
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
168.3
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
168.2
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
167.1
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
167.0
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
165.4
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
164.5
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
164.0
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
164.0
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
161.5
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
158.9
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
157.7
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
157.6
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
154.2
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
153.3
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
153.2
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
152.2
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
150.9
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
149.6
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
144.9
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
143.8
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
143.2
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
142.9
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
139.7
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
139.6
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
138.7
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
137.5
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
137.5
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
136.8
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
136.7
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
136.0
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
135.7
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
134.6
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
134.3
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
133.2
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
129.9
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
127.2
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
126.9
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
124.7
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
121.8
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
121.2
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
121.0
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
120.8
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SELENOF is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
57.5
Number of samples
58
Samples
Sample
Description
TPM
AK117
N, NA, stage:NA, dead, 210 days
94.2
AK139
N, NA, stage:NA, dead, 270 days
93.2
AK153
N, NA, stage:NA, dead, 240 days
87.2
AK099
N, NA, stage:NA, dead, 420 days
81.2
AK236
N, NA, stage:NA, dead, 360 days
76.7
AK199
N, NA, stage:NA, alive, 1860 days
76.7
AK133
N, NA, stage:NA, dead, 360 days
75.7
AK003
N, NA, stage:NA, dead, 600 days
75.6
AK030
N, NA, stage:NA, dead, 120 days
72.9
AK188
N, NA, stage:NA, alive, 420 days
72.9
AK218
N, NA, stage:NA, dead, 180 days
72.8
AK098
N, NA, stage:NA, dead, 660 days
72.5
AK195
N, NA, stage:NA, dead, 390 days
71.1
AK123
N, NA, stage:NA, dead, 180 days
71.1
AK156
N, NA, stage:NA, dead, 330 days
70.3
AK205
N, NA, stage:NA, dead, 120 days
70.0
AK081
N, NA, stage:NA, dead, 180 days
68.2
AK178
N, NA, stage:NA, dead, 240 days
66.6
AK051
N, NA, stage:NA, dead, 360 days
65.7
AK071
N, NA, stage:NA, dead, 540 days
65.0
AK005
N, NA, stage:NA, dead, 240 days
64.7
AK183
N, NA, stage:NA, alive, 360 days
64.1
AK213
N, NA, stage:NA, alive, 2010 days
58.7
AK074
N, NA, stage:NA, alive, 300 days
58.7
AK076
N, NA, stage:NA, alive, 660 days
57.6
AK142
N, NA, stage:NA, alive, 90 days
57.6
AK124
N, NA, stage:NA, alive, 1920 days
57.1
AK068
N, NA, stage:NA, alive, 360 days
56.7
AK035
N, NA, stage:NA, dead, 210 days
56.4
AK072
N, NA, stage:NA, dead, 150 days
56.2
AK091
N, NA, stage:NA, dead, 210 days
55.7
AK227
N, NA, stage:NA, alive, 300 days
55.2
AK173
N, NA, stage:NA, dead, 180 days
55.0
AK079
N, NA, stage:NA, dead, 210 days
54.0
AK167
N, NA, stage:NA, dead, 180 days
52.1
AK216
N, NA, stage:NA, dead, 360 days
52.0
AK066
N, NA, stage:NA, alive, 960 days
50.3
AK055
N, NA, stage:NA, dead, 240 days
49.7
AK100
N, NA, stage:NA, alive, 960 days
49.4
AK089
N, NA, stage:NA, dead, 330 days
49.3
AK158
N, NA, stage:NA, dead, 360 days
48.1
AK185
N, NA, stage:NA, alive, 330 days
47.6
AK226
N, NA, stage:NA, dead, 360 days
46.7
AK049
N, NA, stage:NA, dead, 180 days
46.7
AK103
N, NA, stage:NA, alive, 1320 days
45.7
AK041
N, NA, stage:NA, alive, 810 days
44.9
AK134
N, NA, stage:NA, dead, 360 days
44.7
AK231
N, NA, stage:NA, dead, 240 days
42.9
AK006
N, NA, stage:NA, dead, 360 days
42.2
AK015
N, NA, stage:NA, alive, 720 days
41.3
AK165
N, NA, stage:NA, alive, 360 days
40.0
AK053
N, NA, stage:NA, dead, 300 days
38.1
AK002
N, NA, stage:NA, dead, 570 days
37.0
AK149
N, NA, stage:NA, dead, 420 days
35.6
AK088
N, NA, stage:NA, dead, 360 days
35.1
AK085
N, NA, stage:NA, alive, 660 days
34.2
AK043
N, NA, stage:NA, alive, 660 days
31.7
AK102
N, NA, stage:NA, alive, 1740 days
26.4
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0162100003
Tumor
1.0
CPT0218690004
Tumor
0.9
CPT0206560003
Tumor
0.8
CPT0207090003
Tumor
0.7
CPT0224540004
Tumor
0.6
CPT0168480003
Tumor
0.6
CPT0127480003
Tumor
0.6
CPT0079790003
Tumor
0.6
CPT0089150003
Tumor
0.6
CPT0162020003
Tumor
0.6
CPT0206230003
Tumor
0.6
CPT0205570003
Tumor
0.6
CPT0217430008
Tumor
0.5
CPT0218330004
Tumor
0.5
CPT0093360003
Tumor
0.5
CPT0123530003
Tumor
0.5
CPT0092440003
Tumor
0.4
CPT0168080003
Tumor
0.4
CPT0217000004
Tumor
0.4
CPT0093510003
Tumor
0.4
CPT0206670004
Tumor
0.3
CPT0217880003
Tumor
0.3
CPT0168590003
Tumor
0.3
CPT0161730003
Tumor
0.3
CPT0225760003
Tumor
0.3
CPT0205780003
Tumor
0.3
CPT0093550003
Tumor
0.3
CPT0205890003
Tumor
0.3
CPT0205450004
Tumor
0.3
CPT0218960004
Tumor
0.3
CPT0071100003
Tumor
0.3
CPT0167530003
Tumor
0.3
CPT0087680003
Tumor
0.3
CPT0127420003
Tumor
0.2
CPT0093450003
Tumor
0.2
CPT0228220003
Tumor
0.2
CPT0221180003
Tumor
0.2
CPT0186100003
Tumor
0.2
CPT0168830003
Tumor
0.2
CPT0218830004
Tumor
0.2
CPT0167970003
Tumor
0.2
CPT0189750004
Tumor
0.2
CPT0208980003
Tumor
0.2
CPT0087730003
Tumor
0.2
CPT0217710008
Tumor
0.2
CPT0125570003
Tumor
0.2
CPT0093590003
Tumor
0.2
CPT0171580008
Tumor
0.1
CPT0219080004
Tumor
0.1
CPT0064890003
Tumor
0.1
CPT0217060003
Tumor
0.1
CPT0224390004
Tumor
0.1
CPT0167640003
Tumor
0.1
CPT0078580003
Tumor
0.1
CPT0206880003
Tumor
0.1
CPT0206000004
Tumor
0.1
CPT0206780003
Tumor
0.1
CPT0218890004
Tumor
0.0
CPT0217100003
Tumor
0.0
CPT0190360004
Tumor
0.0
CPT0217190003
Tumor
0.0
CPT0168720003
Tumor
0.0
CPT0168270003
Tumor
0.0
CPT0199770003
Tumor
0.0
CPT0218770003
Tumor
0.0
CPT0189460003
Tumor
0.0
CPT0204420003
Normal
0.0
CPT0182580003
Tumor
-0.1
CPT0189570004
Tumor
-0.1
CPT0218670003
Tumor
-0.1
CPT0167860004
Tumor
-0.1
CPT0125220003
Tumor
-0.1
CPT0182500003
Tumor
-0.1
CPT0125510003
Tumor
-0.1
CPT0162140003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0182550003
Tumor
-0.2
CPT0225730003
Tumor
-0.2
CPT0204360003
Normal
-0.2
CPT0204370003
Normal
-0.2
CPT0175060003
Tumor
-0.2
CPT0206110003
Tumor
-0.2
CPT0206450003
Tumor
-0.2
CPT0104330003
Tumor
-0.2
CPT0087950003
Tumor
-0.2
CPT0002410011
Tumor
-0.2
CPT0205670004
Tumor
-0.2
CPT0087570003
Tumor
-0.2
CPT0104220003
Tumor
-0.2
CPT0209440003
Tumor
-0.2
CPT0196850003
Tumor
-0.2
CPT0167750004
Tumor
-0.3
CPT0204400003
Normal
-0.3
CPT0224600003
Tumor
-0.3
CPT0224330003
Tumor
-0.3
CPT0189250003
Tumor
-0.3
CPT0204340003
Normal
-0.3
CPT0204330003
Normal
-0.4
CPT0204350003
Normal
-0.4
CPT0204390003
Normal
-0.4
CPT0204410003
Normal
-0.4
CPT0201710003
Tumor
-0.4
CPT0207030003
Tumor
-0.5
CPT0206330003
Tumor
-0.5
CPT0168380003
Tumor
-0.5
CPT0204380003
Normal
-0.5
CPT0190240004
Tumor
-0.6
CPT0064650003
Tumor
-0.7
CPT0216920008
Tumor
-0.7
CPT0189650004
Tumor
-0.8
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.